Skip to main content

The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.

Publication ,  Journal Article
Hong, JY; Hong, ME; Choi, MK; Chang, W; Do, I-G; Jo, J-S; Jung, S-H; Park, S; Kim, SJ; Ko, YH; Kim, WS
Published in: Anticancer Res
April 2015

BACKGROUND: The oncogenic PI3K/serine-threonine kinase (PI3K/AKT) pathway is a downstream pathway of B-cell receptor (BCR) signaling pathway and plays a crucial role in the pathogenesis of B-cell lymphoma. However, there have been preclinical data showing PI3K/AKT pathway activation in T-cell lymphoma, with in different mechanisms from those in B-cell lymphoma. In this study, we investigated the impact of p-AKT expression on clinical outcomes of peripheral T-cell lymphoma (PTCL). MATERIALS AND METHODS: We analyzed 63 patients with PTCL [PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) or extranodal natural kiler T-cell lymphoma (NKTCL)]. To define the clinical implications of p-AKT expression in PTCL, we calculated arbitrary units (AUs) by multiplying the intensity and the proportion of p-AKT expression. RESULTS: Based on a cutoff value of the upper limit of the third quartile (Q3) of the AU, 12 patients were classified into the high p-AKT group, while the remaining 51 patients were classified into the low p-AKT group. The overall response rate to frontline chemotherapy was significantly lower in the high p-AKT group than in the low p-AKT group (20.0% vs. 71.1%, p=0.004). The high p-AKT group showed substantially worse overall survival (OS) (median OS=2.3 vs. 25.2 months, p<0.001) and progression-free survival (PFS) (median PFS=1.6 vs. 8.8 months, p<0.001) compared with the low p-AKT group. Multivariate analysis showed that high p-AKT expression remained a significant independent poor prognostic factor for OS (hazard ratio (HR)=7.0; 95% confidence interval (CI)=3.0-16.6; p<0.001) and PFS (HR=6.8; 95% CI=3.0-15.2; p<0.001). CONCLUSION: PTCL patients with high p-AKT expression showed aggressive clinical courses with significantly worse OS and PFS and a poor chemotherapy response rate. We suggest that targeting the PI3K/AKT pathway may be a promising therapeutic strategy for PTCL.

Duke Scholars

Published In

Anticancer Res

EISSN

1791-7530

Publication Date

April 2015

Volume

35

Issue

4

Start / End Page

2465 / 2474

Location

Greece

Related Subject Headings

  • Signal Transduction
  • Prognosis
  • Phosphatidylinositol 3-Kinases
  • Oncology & Carcinogenesis
  • Oncogene Protein v-akt
  • Middle Aged
  • Male
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, Large-Cell, Anaplastic
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hong, J. Y., Hong, M. E., Choi, M. K., Chang, W., Do, I.-G., Jo, J.-S., … Kim, W. S. (2015). The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res, 35(4), 2465–2474.
Hong, Jung Yong, Min Eui Hong, Moon Ki Choi, Wonjin Chang, In-Gu Do, Ji-Suk Jo, Sin-Ho Jung, et al. “The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.Anticancer Res 35, no. 4 (April 2015): 2465–74.
Hong JY, Hong ME, Choi MK, Chang W, Do I-G, Jo J-S, et al. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res. 2015 Apr;35(4):2465–74.
Hong, Jung Yong, et al. “The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.Anticancer Res, vol. 35, no. 4, Apr. 2015, pp. 2465–74.
Hong JY, Hong ME, Choi MK, Chang W, Do I-G, Jo J-S, Jung S-H, Park S, Kim SJ, Ko YH, Kim WS. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res. 2015 Apr;35(4):2465–2474.

Published In

Anticancer Res

EISSN

1791-7530

Publication Date

April 2015

Volume

35

Issue

4

Start / End Page

2465 / 2474

Location

Greece

Related Subject Headings

  • Signal Transduction
  • Prognosis
  • Phosphatidylinositol 3-Kinases
  • Oncology & Carcinogenesis
  • Oncogene Protein v-akt
  • Middle Aged
  • Male
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, Large-Cell, Anaplastic
  • Humans